Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …

Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that
tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (A β). We …

There is a pressing need to capture and track subtle cognitive change at the preclinical
stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity …

The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

Advances in molecular positron emission tomography (PET) have enabled anatomic
tracking of brain pathology in longitudinal studies of normal aging and dementia, including …

Importance A National Institute on Aging and Alzheimer's Association workgroup proposed a
research framework for Alzheimer disease in which biomarker classification of research …

In Alzheimer's disease, post-mortem studies have shown that the first cortical site where
neurofibrillary tangles appear is the transentorhinal region, a subregion within the medial …

Objective To determine the rate of tau accumulation in healthy older adults (OA) and patients
with Alzheimer disease (AD), as well as the relationship of tau accumulation to cortical …